A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer.
MJ Pishvaian,
R Slack,
A Witkiewicz,
AR He,
JJ Hwang,
A Hankin,
K Dorsch-Vogel,
D Kuda,
T McAndrew,
LM Weiner,
others
January 2011